India’s CDMO sector is rapidly expanding, driven by global pharma’s shift away from China, strong regulatory compliance, cost-efficiency, and government…
Kotak Institutional Equities recommends Piramal Pharma, Syngene International, and Indegene as top buys, citing strong growth potential in CRDMOs, pharmaceutical…